Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Center, Open-Label Phase 1b/2 Study of a Novel FGFR3 Inhibitor (B-701) Combined With Pembrolizumab in Subjects With Locally Advanced or Metastatic Urothelial Carcinoma Who Have Progressed Following Platinum-based Chemotherapy

NCT03123055 is registered in ClinicalTrials.gov with Rainier Therapeutics as lead sponsor.

NCT NCT03123055
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03123055 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Center, Open-Label Phase 1b/2 Study of a Novel FGFR3 Inhibitor (B-701) Combined With Pembrolizumab in Subjects With Locally Advanced or Metastatic Urothelial Carcinoma Who Have Progressed Following Platinum-based Chemotherapy
Lead sponsor
Rainier Therapeutics
Phase
Phase 1/2
Overall status
Terminated
Start date
April 20, 2017
Completion date
December 1, 2019
Enrollment
28 (actual)
Sites
52

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced or metastatic urothelial cell carcinoma, urinary bladder disease, urological diseases